Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Oct;36(7):1591-1626.
doi: 10.1007/s11011-021-00806-4. Epub 2021 Aug 13.

Neuroinflammation in neurological disorders: pharmacotherapeutic targets from bench to bedside

Awanish Mishra  1   2 , Ritam Bandopadhyay  3 , Prabhakar Kumar Singh  3 , Pragya Shakti Mishra  4 , Neha Sharma  3 , Navneet Khurana  3
Affiliations
Review

Neuroinflammation in neurological disorders: pharmacotherapeutic targets from bench to bedside

Awanish Mishra et al. Metab Brain Dis. 2021 Oct.

Abstract

Neuroinflammation is one of the host defensive mechanisms through which the nervous system protects itself from pathogenic and or infectious insults. Moreover, neuroinflammation occurs as one of the most common pathological outcomes in various neurological disorders, makes it the promising target. The present review focuses on elaborating the recent advancement in understanding molecular mechanisms of neuroinflammation and its role in the etiopathogenesis of various neurological disorders, especially Alzheimer's disease (AD), Parkinson's disease (PD), and Epilepsy. Furthermore, the current status of anti-inflammatory agents in neurological diseases has been summarized in light of different preclinical and clinical studies. Finally, possible limitations and future directions for the effective use of anti-inflammatory agents in neurological disorders have been discussed.

Keywords: Alzheimer’s disease; Epilepsy; Neuroinflammation; Neurological disorders; Parkinson’s disease.

PubMed Disclaimer

References

    1. Abd Wahab DYA, Gau CH, Zakaria R, Muthu Karuppan MK, A-Rahbi BS, Abdullah Z, Alrafiah A, Abdullah JM, Muthuraju S (2019) Review on Cross talk between neurotransmitters and neuroinflammation in striatum and cerebellum in the mediation of motor behaviour. Biomed Res Int 2019:1767203. https://doi.org/10.1155/2019/1767203 - DOI
    1. Abuelezz SA, Hendawy N (2021) HMGB1/RAGE/TLR4 axis and glutamate as novel targets for PCSK9 inhibitor in high fat cholesterol diet induced cognitive impairment and amyloidosis. Life Sci 273:119310. https://doi.org/10.1016/j.lfs.2021.119310 - DOI - PubMed
    1. Acar G, Tanriover G, Acar F, Demir R (2015) Increased expression of matrix metalloproteinase-9 in patients with temporal lobe epilepsy. Turk Neurosurg 25(5):749–756. https://doi.org/10.5137/1019-5149.JTN.10738-14.0 - DOI - PubMed
    1. Aguirre-Vidal Y, Morales-Montor J, de León CTG, Ostoa-Saloma P, Díaz-Zaragoza M, Montes S, Arteaga-Silva M, Monroy-Noyola A (2020) Protection induced by estradiol benzoate in the MPP+ rat model of Parkinson’s disease is associated with the regulation of the inflammatory cytokine profile in the nigro striatum. J Neuroimmunol 349:577426. https://doi.org/10.1016/j.jneuroim.2020.577426 - DOI - PubMed
    1. Ahuja M, Ammal Kaidery N, Yang L, Calingasan N, Smirnova N, Gaisin A, Gaisina IN, Gazaryan I, Hushpulian DM, Kaddour-Djebbar I, Bollag WB, Morgan JC, Ratan RR, Starkov AA, Beal MF, Thomas B (2016) Distinct Nrf2 signaling mechanisms of fumaric acid esters and their role in neuroprotection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced experimental Parkinson’s-like disease. J Neurosci 36(23):6332–6351. https://doi.org/10.1523/JNEUROSCI.0426-16.2016 - DOI - PubMed - PMC

MeSH terms

LinkOut - more resources